Company intelligence / Profile preview

Biocrucible

Cambridge / Saffron Walden / Great Abington / Little Chesterford, England, United Kingdombiocrucible.co.uk ↗

Ownership: Private
Employees: ~71
Development stage: Preclinical

Overview

Biocrucible has developed proprietary molecular diagnostic devices using ultra-fast isothermal nucleic acid amplification, enabling near-patient and at-home testing for infectious diseases and genetic conditions. Their Molten TagsTM technology accelerates biochemical kinetics to improve life science and diagnostic workflows. The company holds patents in biochemistry, molecular biology, and polymer chemistry. Clinical results are not applicable as the company focuses on diagnostics rather than therapeutics.

Therapeutic areas: Rare DiseasesInfectious Diseases
Modalities: Diagnostic deviceIn vitro diagnosticsMolecular diagnostics (Isothermal nucleic acid amplification)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Biocrucible.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocrucible.

Explore the full profile